Pharmacological treatments for eosinophilic esophagitis: current options and emerging therapies

References

• Lucendo AJ, Molina-Infante J, Arias A, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United Eur Gastroenterol J. 2017;5(3):335–358.
   PubMed Web of Science ®Google Scholar
• Navarro P, Arias Á, Arias-González L, et al. Systematic review with meta-analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment Pharmacol Ther. 2019;49(9):1116–1125.
   PubMed Web of Science ®Google Scholar
• Arias Á, Lucendo AJ. Incidence and prevalence of eosinophilic oesophagitis increase continuously in adults and children in central Spain: A 12-year population-based study. Dig Liver Dis. 2019;51(1):55–62.
   PubMedGoogle Scholar
• Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. Gastroenterology. 2018;154(2):319–332.
   PubMed Web of Science ®Google Scholar
• Greuter T, Bussmann C, Safroneeva E, et al. Long-term treatment of eosinophilic esophagitis with swallowed topical corticosteroids: development and evaluation of a therapeutic concept. Am J Gastroenterol. 2017;112(10):1527–1535.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Kim HP, Sperry SLW, et al. A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. Gastrointest Endosc. 2014;79(4):577–585.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology. 2013;145(6):1230–1236.
   PubMed Web of Science ®Google Scholar
• Lipka S, Kumar A, Richter JE. Impact of diagnostic delay and other risk factors on eosinophilic esophagitis phenotype and esophageal diameter. J Clin Gastroenterol. 2016;50(2):134–140.
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, Arias-González L, Molina-Infante J, et al. Systematic review: health-related quality of life in children and adults with eosinophilic oesophagitis—measure instruments and determinant factors. Aliment Pharmacol Ther. 2017;46(4):401–409.
   PubMed Web of Science ®Google Scholar
• Safroneeva E, Balsiger L, Hafner D, et al. Adults with eosinophilic oesophagitis identify symptoms and quality of life as the most important outcomes. Aliment Pharmacol Ther. 2018;48(10):1082–1090.
   PubMed Web of Science ®Google Scholar
• Attwood SE, Smyrk TC, Demeester TR, et al. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig Dis Sci. 1993;38(1):109–116.
   PubMed Web of Science ®Google Scholar
• Straumann A, Spichtin HP, Bernoulli R, et al. [Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings]. Schweiz Med Wochenschr. 1994;124(33):1419–1429.
   PubMedGoogle Scholar
• Arias Á, Lucendo AJ. Molecular basis and cellular mechanisms of eosinophilic esophagitis for the clinical practice. Expert Rev Gastroenterol Hepatol. 2019;13(2):99–117.
   PubMed Web of Science ®Google Scholar
• Kelly KJ, Lazenby AJ, Rowe PC, et al. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology. 1995;109(5):1503–1512.
   PubMed Web of Science ®Google Scholar
• Arias A, Gonzalez-Cervera J, Tenias JM, et al. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology. 2014;146(7):1639–1648.
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Lucendo AJ. Dietary therapy for eosinophilic esophagitis. J Allergy Clin Immunol. 2018;142(1):41–47.
   PubMed Web of Science ®Google Scholar
• Chuang M-YA, Chinnaratha MA, Hancock DG, et al. Topical steroid therapy for the treatment of eosinophilic esophagitis (EoE): a systematic review and meta-analysis. Clin Transl Gastroenterol. 2015;6:e82.
   PubMed Web of Science ®Google Scholar
• Sawas T, Dhalla S, Sayyar M, et al. Systematic review with meta-analysis: pharmacological interventions for eosinophilic oesophagitis. Aliment Pharmacol Ther. 2015;41(9):797–806.
   PubMed Web of Science ®Google Scholar
• Murali AR, Gupta A, Attar BM, et al. Topical steroids in eosinophilic esophagitis: systematic review and meta-analysis of placebo-controlled randomized clinical trials. J Gastroenterol Hepatol. 2016;31(6):1111–1119.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Katzka DA, Collins MH, et al. Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis. Gastroenterology. 2017;152(4):776–786.
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, Miehlke S, Schlag C, et al. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial. Gastroenterology. 2019;157(1):74–86.
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Lucendo AJ. Proton pump inhibitor therapy for eosinophilic esophagitis: a paradigm shift. Am J Gastroenterol. 2017;112(12):1770–1773.
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, Arias A, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(1):13–22.
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Rodriguez-Sanchez J, Martinek J, et al. Long-term loss of response in proton pump inhibitor-responsive Esophageal eosinophilia is uncommon and influenced by CYP2C19 genotype and rhinoconjunctivitis. Am J Gastroenterol. 2015;110(11):1567–1575.
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Junquera C, Fernández-Fernández S, Cilleruelo ML, et al. High prevalence of response to proton-pump inhibitor treatment in children with esophageal eosinophilia. J Pediatr Gastroenterol Nutr. 2016;62(5):704–710.
   PubMed Web of Science ®Google Scholar
• Gómez-Torrijos E, García-Rodríguez R, Castro-Jiménez A, et al. The efficacy of step-down therapy in adult patients with proton pump inhibitor-responsive oesophageal eosinophilia. Aliment Pharmacol Ther. 2016;43(4):534–540.
   PubMed Web of Science ®Google Scholar
• Moawad FJ, Molina-Infante J, Lucendo AJ, et al. Systematic review with meta-analysis: endoscopic dilation is highly effective and safe in children and adults with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2017;46(2):96–105.
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, Molina-Infante J. Esophageal dilation in eosinophilic esophagitis: risks, benefits, and when to do it. Curr Opin Gastroenterol. 2018;34(4):226–232.
   PubMed Web of Science ®Google Scholar
• Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007;133(4):1342–1363.
   PubMed Web of Science ®Google Scholar
• Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128(1):3–20.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterology. 2018;155(4):1022–1033.
   PubMed Web of Science ®Google Scholar
• Peery AF, Shaheen NJ, Dellon ES. Practice patterns for the evaluation and treatment of eosinophilic oesophagitis. Aliment Pharmacol Ther. 2010;32(11–12):1373–1382.
   PubMed Web of Science ®Google Scholar
• Spergel JM, Book WM, Mays E, et al. Variation in prevalence, diagnostic criteria, and initial management options for eosinophilic gastrointestinal diseases in the United States. J Pediatr Gastroenterol Nutr. 2011;52(3):300–306.
   PubMed Web of Science ®Google Scholar
• Miehlke S, von Arnim U, Schlag C, et al. Clinical management of eosinophilic esophagitis - a nationwide survey among gastroenterologists in Germany. Z Gastroenterol. 2019;57(6):745–752.
   PubMed Web of Science ®Google Scholar
• Huang KZ, Jensen ET, Chen HX, et al. Practice pattern variation in pediatric eosinophilic esophagitis in the carolinas EoE collaborative: a research model in community and academic practices. South Med J. 2018;111(6):328–332.
   PubMed Web of Science ®Google Scholar
• Vermeulen BD, Bogte A, Verhagen MA, et al. Management of eosinophilic esophagitis in daily clinical practice. Dis Esophagus. 2018;31(2). DOI:10.1093/dote/dox119
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Schoepfer AM, Lucendo AJ, et al. Eosinophilic esophagitis: what can we learn from Crohn’s disease? United Eur Gastroenterol J. 2017;5(6):762–772.
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Lucendo AJ. Eosinophilic esophagitis: a practical approach to diagnosis and management. Expert Rev Gastroenterol Hepatol. 2014;8(8):925–934.
   PubMed Web of Science ®Google Scholar
• Pineton de Chambrun G, Blanc P, Peyrin-Biroulet L. Current evidence supporting mucosal healing and deep remission as important treatment goals for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2016;10(8):915–927.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Gupta SK. A conceptual approach to understanding treatment response in eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2019. DOI:10.1016/j.cgh.2019.01.030.
   Web of Science ®Google Scholar
• Lucendo AJ, Molina-Infante J. Eosinophilic oesophagitis: current evidence-based diagnosis and treatment. Gastroenterol Hepatol. 2018;41(4):281–291.
   PubMed Web of Science ®Google Scholar
• Reed CC, Koutlas NT, Robey BS, et al. Prolonged time to diagnosis of eosinophilic esophagitis despite increasing knowledge of the disease. Clin Gastroenterol Hepatol. 2018;16(10):1667–1669.
   PubMed Web of Science ®Google Scholar
• Collins MH, Martin LJ, Alexander ES, et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus. 2017;30(3):1–8.
   PubMed Web of Science ®Google Scholar
• Warners MJ, Ambarus CA, Bredenoord AJ, et al. Reliability of histologic assessment in patients with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2018;47(7):940–950.
   PubMed Web of Science ®Google Scholar
• Hirano I, Collins MH, Assouline-Dayan Y, et al. RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis. Gastroenterology. 2019;156(3):592–603.
   PubMed Web of Science ®Google Scholar
• Alexander JA, Jung KW, Arora AS, et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2012;10(7):742–749.
   PubMed Web of Science ®Google Scholar
• Larsson H, Norder Grusell E, Tegtmeyer B, et al. Grade of eosinophilia versus symptoms in patients with dysphagia and esophageal eosinophilia. Dis Esophagus. 2016;29(8):971–976.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Irani A-M, Hill MR, et al. Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis. Aliment Pharmacol Ther. 2013;38(6):634–642.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Straumann A, Panczak R, et al. Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis. Gastroenterology. 2014;147(6):1255–1266.
   PubMed Web of Science ®Google Scholar
• Franciosi JP, Hommel KA, DeBrosse CW, et al. Development of a validated patient-reported symptom metric for pediatric eosinophilic esophagitis: qualitative methods. BMC Gastroenterol. 2011;11:126.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Panczak R, Zwahlen M, et al. How do gastroenterologists assess overall activity of eosinophilic esophagitis in adult patients? Am J Gastroenterol. 2015;110(3):402–414.
   PubMed Web of Science ®Google Scholar
• Safroneeva E, Straumann A, Coslovsky M, et al. Symptoms have modest accuracy in detecting endoscopic and histologic remission in adults with eosinophilic esophagitis. Gastroenterology. 2016;150(3):581–590.
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, Molina-Infante J. Limitation of symptoms as predictors of remission in eosinophilic esophagitis: the need to go beyond endoscopy and histology. Gastroenterology. 2016;150(3):547–549.
   PubMed Web of Science ®Google Scholar
• Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut. 2013;62:489–495.
   PubMed Web of Science ®Google Scholar
• Spechler SJ. Eosinophilic esophagitis: novel concepts regarding pathogenesis and clinical manifestations. J Gastroenterol. 2019. DOI:10.1007/s00535-019-01604-7
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Van Rhijn BD. Interactions between gastro-oesophageal reflux disease and eosinophilic oesophagitis. Best Pract Res Clin Gastroenterol. 2015;29(5):749–758.
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Bredenoord AJ, Cheng E, et al. Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut. 2016;65(3):521–531.
   Web of Science ®Google Scholar
• Molina-Infante J, Rivas MD, Hernandez-Alonso M, et al. Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression. Aliment Pharmacol Ther. 2014;40(8):955–965.
   PubMed Web of Science ®Google Scholar
• Cury EK, Schraibman V, Faintuch S. Eosinophilic infiltration of the esophagus: gastroesophageal reflux versus eosinophilic esophagitis in children–discussion on daily practice. J Pediatr Surg. 2004;39(2):e4–7.
   PubMed Web of Science ®Google Scholar
• Ngo P, Furuta GT, Antonioli DA, et al. Eosinophils in the esophagus–peptic or allergic eosinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gastroenterol. 2006;101(7):1666–1670.
   PubMed Web of Science ®Google Scholar
• Sayej WN, Patel R, Baker RD, et al. Treatment with high-dose proton pump inhibitors helps distinguish eosinophilic esophagitis from noneosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2009;49(4):393–399.
   PubMed Web of Science ®Google Scholar
• Moawad FJ, Veerappan GR, Dias JA, et al. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. Am J Gastroenterol. 2013;108(3):366–372.
   PubMed Web of Science ®Google Scholar
• Vazquez-Elizondo G, Ngamruengphong S, Khrisna M, et al. The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor. Aliment Pharmacol Ther. 2013;38(10):1312–1319.
   PubMed Web of Science ®Google Scholar
• Faubion WA, Perrault J, Burgart LJ, et al. Treatment of eosinophilic esophagitis with inhaled corticosteroids. J Pediatr Gastroenterol Nutr. 1998;27(1):90–93.
   PubMed Web of Science ®Google Scholar
• Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol. 2008;6(2):165–173.
   PubMed Web of Science ®Google Scholar
• Tan ND, Xiao YL, Chen MH. Steroids therapy for eosinophilic esophagitis: systematic review and meta-analysis. J Dig Dis. 2015;16(8):431–442.
   PubMed Web of Science ®Google Scholar
• Lipka S, Kumar A, Miladinovic B, et al. Systematic review with network meta-analysis: comparative effectiveness of topical steroids vs. PPIs for the treatment of the spectrum of eosinophilic oesophagitis. Aliment Pharmacol Ther. 2016;43(6):663–673.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Sheikh A, Speck O, et al. Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology. 2012;143:321–324.
   PubMed Web of Science ®Google Scholar
• Straumann A, Conus S, Degen L, et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2011;9(5):400–409.
   PubMed Web of Science ®Google Scholar
• Butz BK, Wen T, Gleich GJ, et al. Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis. Gastroenterology. 2014;147(2):324–333.
   PubMed Web of Science ®Google Scholar
• Lucendo A, Miehlke S, Vieth M, et al. Budesonide orodispersible tablets are highly effective to maintain clinico-histological remission in adult patients with eosinophilic esophagitis: results from the 48-weeks, double-blind, placebo-controlled, pivotal Eos-2 trial. Gastroenterology. 2019;156(6):S–1509.
   Google Scholar
• Miehlke S, Hruz P, Vieth M, et al. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. Gut. 2016;65(3):390–399.
   PubMed Web of Science ®Google Scholar
• Harel S, Hursh BE, Chan ES, et al. Adrenal suppression in children treated with oral viscous budesonide for eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2015;61(2):190–193.
   PubMed Web of Science ®Google Scholar
• Hsu S, Wood C, Pan Z, et al. Adrenal Insufficiency in pediatric eosinophilic esophagitis patients treated with swallowed topical steroids. Pediatr Allergy Immunol Pulmonol. 2017;30(3):135–140.
   PubMed Web of Science ®Google Scholar
• Ahmet A, Benchimol EI, Goldbloom EB, et al. Adrenal suppression in children treated with swallowed fluticasone and oral viscous budesonide for eosinophilic esophagitis. Allergy Asthma Clin Immunol. 2016;12:49.
   PubMed Web of Science ®Google Scholar
• Schoelwer MJ, Nebesio TD. Diagnosis of adrenal insufficiency in eosinophilic esophagitis: the importance of timing of cortisol measurements in interpreting low-dose adrenocorticotropic hormone stimulation testing. J Pediatr. 2016;174:282.
   PubMed Web of Science ®Google Scholar
• Philpott H, Dougherty MK, Reed CC, et al. Systematic review: adrenal insufficiency secondary to swallowed topical corticosteroids in eosinophilic oesophagitis. Aliment Pharmacol Ther. 2018;47(8):1071–1078.
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Arias Á, Alcedo J, et al. Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: the 2-4-6 study. J Allergy Clin Immunol. 2018;141(4):1365–1372.
   PubMed Web of Science ®Google Scholar
• Nassar Y, Richter S. Proton-pump inhibitor use and fracture risk: an updated systematic review and meta-analysis. J Bone Metab. 2018;25(3):141–151.
   PubMedGoogle Scholar
• Sun J, Sun H, Cui M, et al. The use of anti-ulcer agents and the risk of chronic kidney disease: a meta-analysis. Int Urol Nephrol. 2018;50(10):1835–1843.
   PubMed Web of Science ®Google Scholar
• Greuter T, Alexander JA, Straumann A, et al. Diagnostic and therapeutic long-term management of eosinophilic esophagitis- current concepts and perspectives for steroid use. Clin Transl Gastroenterol. 2018;9(12):e212.
   PubMedGoogle Scholar
• Eyerich S, Metz M, Bossios A, et al. New biological treatments for asthma and skin allergies. Allergy. 2019. DOI:10.1111/all.14027.
   PubMedGoogle Scholar
• Straumann A, Bussmann C, Conus S, et al. Anti-TNF-alpha (infliximab) therapy for severe adult eosinophilic esophagitis. J Allergy Clin Immunol. 2008;122(2):425–427.
   PubMed Web of Science ®Google Scholar
• Straumann A, Bauer M, Fischer B, et al. Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. J Allergy Clin Immunol. 2001;108(6):954–961.
   PubMed Web of Science ®Google Scholar
• Philpott H, Thien F. The role of allergy testing in eosinophilic esophagitis: an update of the evidence. Curr Treat Options Gastroenterol. 2017;15(1):26–34.
   PubMedGoogle Scholar
• Takhar P, Corrigan CJ, Smurthwaite L, et al. Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol. 2007;119(1):213–218.
   PubMed Web of Science ®Google Scholar
• Takhar P, Smurthwaite L, Coker HA, et al. Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol. 2005;174(8):5024–5032.
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, Navarro M, Comas C, et al. Immunophenotypic characterization and quantification of the epithelial inflammatory infiltrate in eosinophilic esophagitis through stereology: an analysis of the cellular mechanisms of the disease and the immunologic capacity of the esophagus. Am J Surg Pathol. 2007;31(4):598–606.
   PubMed Web of Science ®Google Scholar
• Vicario M, Blanchard C, Stringer KF, et al. Local B cells and IgE production in the oesophageal mucosa in eosinophilic oesophagitis. Gut. 2010;59(1):12–20.
   PubMed Web of Science ®Google Scholar
• Clayton F, Fang JC, Gleich GJ, et al. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. Gastroenterology. 2014;147(3):602–609.
   PubMed Web of Science ®Google Scholar
• Nhu QM, Chiao H, Moawad FJ, et al. The anti-α4β7 integrin therapeutic antibody for inflammatory bowel disease, vedolizumab, ameliorates eosinophilic esophagitis: a novel clinical observation. Am J Gastroenterol. 2018;113(8):1261–1263.
   PubMed Web of Science ®Google Scholar
• Kim HP, Reed CC, Herfarth HH, et al. Vedolizumab treatment may reduce steroid burden and improve histology in patients with eosinophilic gastroenteritis. Clin Gastroenterol Hepatol. 2018;16:1992–1994.
   PubMed Web of Science ®Google Scholar
• Grandinetti T, Biedermann L, Bussmann C, et al. Eosinophilic gastroenteritis: clinical manifestation, natural course, and evaluation of treatment with corticosteroids and vedolizumab. Dig Dis Sci. 2019;64:2231–2241.
   PubMed Web of Science ®Google Scholar
• Mishra A, Hogan SP, Brandt EB, et al. An etiological role for aeroallergens and eosinophils in experimental esophagitis. J Clin Invest. 2001;107(1):83–90.
   PubMed Web of Science ®Google Scholar
• Akei HS, Mishra A, Blanchard C, et al. Epicutaneous antigen exposure primes for experimental eosinophilic esophagitis in mice. Gastroenterology. 2005;129(3):985–994.
   PubMed Web of Science ®Google Scholar
• Mishra A, Hogan SP, Brandt EB, et al. IL-5 promotes eosinophil trafficking to the esophagus. J Immunol. 2002;168(5):2464–2469.
   PubMed Web of Science ®Google Scholar
• Yamazaki K, Murray JA, Arora AS, et al. Allergen-specific in vitro cytokine production in adult patients with eosinophilic esophagitis. Dig Dis Sci. 2006;51(11):1934–1941.
   PubMed Web of Science ®Google Scholar
• Bullock JZ, Villanueva JM, Blanchard C, et al. Interplay of adaptive th2 immunity with eotaxin-3/c-C chemokine receptor 3 in eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2007;45(1):22–31.
   PubMed Web of Science ®Google Scholar
• Farne HA, Wilson A, Powell C, et al. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:CD010834.
   PubMed Web of Science ®Google Scholar
• Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017;140(4):1024–1031.
   PubMed Web of Science ®Google Scholar
• Assa’ad AH, Gupta SK, Collins MH, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology. 2011;141(5):1593–1604.
   PubMed Web of Science ®Google Scholar
• Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: A randomised, placebo-controlled, double-blind trial. Gut. 2010;59(1):21–30.
   PubMed Web of Science ®Google Scholar
• Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2012;129(2):456–463.
   PubMed Web of Science ®Google Scholar
• Markowitz JE, Jobe L, Miller M, et al. Safety and efficacy of reslizumab for children and adolescents with eosinophilic esophagitis treated for 9 years. J Pediatr Gastroenterol Nutr. 2018;66(6):893–897.
   PubMed Web of Science ®Google Scholar
• Schmid-Grendelmeier P, Altznauer F, Fischer B, et al. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol. 2002;169(2):1021–1027.
   PubMed Web of Science ®Google Scholar
• Neilsen CV, Bryce PJ. Interleukin-13 directly promotes oesophagus production of CCL11 and CCL24 and the migration of eosinophils. Clin Exp Allergy. 2010;40(3):427–434.
   PubMed Web of Science ®Google Scholar
• Davis BP, Stucke EM, Khorki ME, et al. Eosinophilic esophagitis-linked calpain 14 is an IL-13-induced protease that mediates esophageal epithelial barrier impairment. JCI Insight. 2016;1(4):e86355.
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Wen T, Greenberg A, et al. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015;135(2):500–507.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Collins MH, Assouline-Dayan Y, et al. Long-term efficacy and safety of RPC4046, an anti-interleukin-13 monoclonal antibody, in patients with eosinophilic esophagitis: results from the open-label extension of the HEROES study. J Allergy Clin Immunol. 2019;143(2):AB208.
   Web of Science ®Google Scholar
• Vatrella A, Fabozzi I, Calabrese C, et al. Dupilumab: a novel treatment for asthma. J Asthma Allergy. 2014;7:123–130.
   PubMedGoogle Scholar
• Wenzel SE, Wang L, Pirozzi G. Dupilumab in persistent asthma. N Engl J Med. 2013;369(13):1276.
   PubMedGoogle Scholar
• Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139.
   PubMed Web of Science ®Google Scholar
• Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology. 2020;158(1):111–122.
   Web of Science ®Google Scholar
• Diaz P, Galleguillos FR, Gonzalez MC, et al. Bronchoalveolar lavage in asthma: the effect of disodium cromoglycate (cromolyn) on leukocyte counts, immunoglobulins, and complement. J Allergy Clin Immunol. 1984;74(1):41–48.
   PubMed Web of Science ®Google Scholar
• Lindqvist A, Karjalainen E-M, Laitinen LA, et al. Salmeterol resolves airway obstruction but does not possess anti-eosinophil efficacy in newly diagnosed asthma: a randomized, double-blind, parallel group biopsy study comparing the effects of salmeterol, fluticasone propionate, and disodium cromoglycate. J Allergy Clin Immunol. 2003;112(1):23–28.
   PubMed Web of Science ®Google Scholar
• Liacouras CA, Spergel JM, Ruchelli E, et al. Eosinophilic esophagitis: a 10-year experience in 381 children. Clin Gastroenterol Hepatol. 2005;3(12):1198–1206.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Zhang J, Whitworth J, et al. A randomized, double-blinded, placebo-controlled study of the use of viscous oral cromolyn sodium for the treatment of eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2018;120(5):527–531.
   PubMed Web of Science ®Google Scholar
• Cikler E, Ersoy Y, Cetinel S, et al. The leukotriene d4 receptor antagonist, montelukast, inhibits mast cell degranulation in the dermis induced by water avoidance stress. Acta Histochem. 2009;111(2):112–118.
   PubMed Web of Science ®Google Scholar
• Ersoy Y, Cikler E, Cetinel S, et al. Leukotriene D4 receptor antagonist montelukast alleviates water avoidance stress-induced degeneration of the gastrointestinal mucosa. Prostaglandins Leukot Essent Fatty Acids. 2008;78(3):189–197.
   PubMed Web of Science ®Google Scholar
• Stumphy J, Al-Zubeidi D, Guerin L, et al. Observations on use of montelukast in pediatric eosinophilic esophagitis: insights for the future. Dis Esophagus. 2011;24(4):229–234.
   PubMed Web of Science ®Google Scholar
• Lucendo AJ, De Rezende LC, Jimenez-Contreras S, et al. Montelukast was inefficient in maintaining steroid-induced remission in adult eosinophilic esophagitis. Dig Dis Sci. 2011;56(12):3551–3558.
   PubMed Web of Science ®Google Scholar
• Alexander JA, Ravi K, Enders FT, et al. Montelukast does not maintain symptom remission after topical steroid therapy for eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2017;15(2):214–221.
   PubMed Web of Science ®Google Scholar
• Pettipher R. The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses. Br J Pharmacol. 2008;153(Suppl 1):S191–199.
   PubMed Web of Science ®Google Scholar
• Straumann A, Hoesli S, Bussmann C, et al. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy. 2013;68(3):375–385.
   PubMed Web of Science ®Google Scholar
• Rothenberg ME. Molecular, genetic, and cellular bases for treating eosinophilic esophagitis. Gastroenterology. 2015;148(6):1143–1157.
   PubMed Web of Science ®Google Scholar
• Noti M, Wojno EDT, Kim BS, et al. Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis. Nat Med. 2013;19(8):1005–1013.
   PubMed Web of Science ®Google Scholar
• Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936–946.
   PubMed Web of Science ®Google Scholar
• Neighbour H, Boulet L-P, Lemiere C, et al. Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2014;44(4):508–516.
   PubMed Web of Science ®Google Scholar
• Youngblood BA, Brock EC, Leung J, et al. Siglec-8 antibody reduces eosinophils and mast cells in a transgenic mouse model of eosinophilic gastroenteritis. JCI Insight. 2019 Oct 3;4(19):126219.
   PubMed Web of Science ®Google Scholar
• Runge TM, Eluri S, Woosley JT, et al. Control of inflammation decreases the need for subsequent esophageal dilation in patients with eosinophilic esophagitis. Dis Esophagus. 2017;30:1–7.
   PubMed Web of Science ®Google Scholar
• Cotton CC, Durban R, Dellon ES. Illuminating elimination diets: controversies regarding dietary treatment of eosinophilic esophagitis. Dig Dis Sci. 2019;64:1401–1408.
   PubMed Web of Science ®Google Scholar
• de Rooij WE, Dellon ES, Parker CE, et al. Pharmacotherapies for the treatment of eosinophilic esophagitis: state of the art review. Drugs. 2019;79:1419–1434.
   PubMed Web of Science ®Google Scholar
• Loke YK, Gilbert D, Thavarajah M, et al. Bone mineral density and fracture risk with long-term use of inhaled corticosteroids in patients with asthma: systematic review and meta-analysis. BMJ Open. 2015;5:e008554.
   PubMed Web of Science ®Google Scholar
• Yeo SH, Aggarwal B, Shantakumar S, et al. Efficacy and safety of inhaled corticosteroids relative to fluticasone propionate: a systematic review of randomized controlled trials in asthma. Expert Rev Respir Med. 2017;11:763–778.
   PubMed Web of Science ®Google Scholar
• Cross RK. Safety considerations with the use of corticosteroids and biologic therapies in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2017;23:1689–1701.
   PubMed Web of Science ®Google Scholar
• Pichler WJ. Adverse side-effects to biological agents. Allergy. 2006;61:912–920.
   PubMed Web of Science ®Google Scholar
• Aubin F, Carbonnel F, Wendling D. The complexity of adverse side-effects to biological agents. J Crohns Colitis. 2013;7:257–262.
   PubMed Web of Science ®Google Scholar
• Aranez V, Ambrus J Jr. Immunologic adverse effects of biologics for the treatment of atopy. Clin Rev Allergy Immunol. 2019. DOI:10.1007/s12016-019-08739-8
   PubMedGoogle Scholar
• Dellon ES. Cost-effective care in eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2019;123(2):166–172.
   PubMed Web of Science ®Google Scholar